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In the phase III registration studies conducted in Japan, Japanese HCV gt1 patients administered vani-
previr 300 mg twice daily plus pegylated interferon/ribavirin for 12 or 24 weeks achieved SVR24 rates of
83.7e84.5% among treatment-naïve patients, and 92.0e96.2% and 61.9% among breakthrough/relapsers
or null-responders to prior interferon based therapy. As evidenced by direct sequencing, patients who
did not achieve SVR24 principally failed due to treatment-emerging mutations at D168 or in a few cases
R155. In this work, additional sequence analysis was conducted to address whether there were baseline
polymorphisms associated with failure, evaluate the persistence of resistant virus among treatment
failures, and assess for evidence of second site co-evolution with R155 or D168 mutations. To accomplish
this, clonal sequencing (up to 40 clones per sample) was conducted on baseline, failure, and follow-up
samples from all 38 patients among the vaniprevir treatment arms who met virologic failure criteria
(37 gt1b, 1 gt1a, herein referred to as virologic failures) and baseline samples from 41 vaniprevir-treated
SVR24 patients (all gt1b) selected among the three studies. SVR24 and virologic failure patients showed
similar distributions of baseline polymorphisms previously associated with failure to one or more pro-
tease inhibitors. Furthermore, there was no evidence for baseline polymorphisms or a genetic signature
across the NS3 protease domain speciﬁc to virologic failure patients, and which distinguishes them from
baseline SVR24 sequences beyond a chance distribution. 24 of 32 virologic failures for whom baseline,
failure, and follow-up samples were available showed reduced prevalence of the resistant virus ﬁrst
observed at the time of failure during the protocol-deﬁned follow-up period of 24 weeks. Finally, pair-
wise analysis using either alignment or phylogenetic based methodologies provided no evidence for
second site evolution with either the R155 or D168 mutations attributed to failure. This work supports
and extends earlier ﬁndings based upon direct sequencing that attributed virologic failure to vaniprevir
in the Phase III studies solely to the emergence of R155 or D168 mutations, with no apparent inﬂuence by
other residues within the NS3 protease domain on treatment outcome.
ClinicalTrials.govIdentiﬁers: NCT01370642, NCT01405937, NCT01405560
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).. Ludmerer).
r B.V. This is an open access article1. Introduction
There are estimated to be 2million Japanese chronically infected
with Hepatitis C virus (HCV) (Chung et al., 2010). The majority
(~70%) are infected with gt1b, while gt2a or gt2b infections account
for most of the remainder (Chung et al., 2010). The prevalence ofunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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(Asahina et al., 2010). Advanced age and advanced ﬁbrosis are
identiﬁed as risk factors for the development of hepatocellular
carcinoma (HCC), and approximately 70% of HCC cases in Japan are
attributed to chronic HCV infection (Editors of the Drafting
Committee for Hepatitis Management Guidelines: The Japan
Society of Hepatology (2013); Umemura et al., 2009). Until
recently pegylated interferon plus ribavirin (Peg-IFN/R) was the
standard treatment option for chronic HCV infection (Manns et al.,
2001; McHutchison et al., 1998). The regimen is poorly tolerated
and is only modestly efﬁcacious against the most prevalent geno-
type in Japan, gt1b, with a response rate of approximately 50%. The
protease inhibitors telaprevir (Kumada et al., 2012) or simeprevir
(Hayashi et al., 2014; Izumi et al., 2014; Kumada et al., 2015) were
approved for use in Japan in 2011 and 2013 respectively as com-
ponents of triple combination regimens with Peg-IFN/R, and both
generate higher response rates in gt1 infected treatment naive
patients. Vaniprevir plus Peg-IFN/R was approved in 2014 for both
treatment naïve patients and prior Peg-IFN/R treatment failures or
null-responders with gt1 infections (Hayashi et al., 2016; Kumada
et al., 2016). In addition, the all oral combinations of daclatasvir
(NS5A inhibitor) and asunaprevir (protease inhibitor) for gt1 pa-
tients who are intolerant to Peg-IFN (Kumada et al., 2014), or
sofosbuvir (NS5B nucleoside inhibitor) and ribavirin for gt2 pa-
tients (Omata et al., 2014), were approved in 2014 and 2015
respectively. The combination of sofosbuvir and ledipasvir (NS5A
inhibitor) was also recently approved in 2015 for treatment naïve
and treatment experienced genotype 1 patients (Mizokami et al.,
2015).
Vaniprevir (MK-7009) is a potent macrocyclic peptide mimetic
inhibitor of HCV NS3/4A protease (Liverton et al., 2010; McCauley
et al., 2010). In Phase III registration trials conducted in Japan in
gt1 patients, vaniprevir in combination with Peg-IFN/R achieved
high cure rates (SVR24). The SVR24 rates for treatment-naïve pa-
tients (protocol PN043, 97.5% gt1b, 2.5% gt1a) receiving 12 or 24
weeks of MK-7009 (300 mg twice daily, b.i.d.) plus Peg-IFN/R were
83.7% and 84.5% versus 55.1% for the control placebo plus Peg-IFN/R
arm (Hayashi et al., 2016). In gt1b patients who relapsed or expe-
rienced breakthrough following prior IFN-based treatment (IFNa,
IFNb, or Peg-IFN, protocol PN044), 12 or 24 weeks of vaniprevir
(300 mg b.i.d.) plus Peg-IFN/R achieved SVR24 rates of 92.0% and
96.2% respectively (Kumada et al., 2016). Finally, in gt1b patients
who previously failed to respond to earlier IFN-based treatment
(IFNa, IFNb, or Peg-IFN, protocol PN045), an SVR24 rate of 61.9% was
achievedwith 24weeks of vaniprevir (300mg b.i.d.) plus Peg-IFN/R
(Kumada et al., 2016).
Among those patients who did not achieve SVR24 to vaniprevir-
based treatment in these studies, failure was principally attributed
to the emergence of viral resistance, speciﬁcally mutations at NS3
D168 or in a few cases R155 (Hayashi et al., 2016; Kumada et al.,
2016). The analysis was conducted by direct sequencing (some-
times called population-based sequencing) which has a detection
limit of approximately 25%. By this analysis, mutations at D168 or
R155 were not present at baseline, emerged during treatment and
were observed at failure for the majority of those patients who
failed a regimen which included vaniprevir.
The present work builds upon the foundation laid by the direct
sequencing analysis and was conducted to address several addi-
tional questions regarding viral resistance observed during these
studies. First, what is the general impact of baseline resistance
associated variants (RAVs), collectively deﬁned to protease in-
hibitors as a class, to vaniprevir-based treatment outcome, and is
there evidence for a genetic signature associated with the non-
SVR state? Second, for those patients who failed treatment due
to viral resistance, can the prevalence of resistant virus bequantiﬁably demonstrated to have diminished during the
protocol-deﬁned follow-up period of 24 weeks following cessa-
tion of treatment? Lastly, are there additional genetic de-
terminants encoded within the protease domain linked to the
emergence of R155 or D168 mutations associated with failure to
vaniprevir-based treatment?
To address these questions, NS3/4A RT-PCR amplicons previ-
ously isolated from PhIII study samples served as sourcematerial to
generate and sequence individual clonal isolates (40 clones per
amplicon) of the NS3 protease domain (amino acids 1e181),
enabling a more sensitive and quantitative assessment of the
prevalence of resistance mutations. Clonal sequencing also pro-
vides linkage data between canonical resistance mutations and
other possible second site mutations, and hence was employed for
this work. The data set was further evaluated for evidence of
phylogenetic co-variation, speciﬁcally interrogating whether drug
induced resistance mutations arose concurrently with other spe-
ciﬁc mutations. This work summarizes the ﬁndings of the clonal
sequencing and the insights it provides into resistance to vaniprevir
as observed in its Phase III registration trials.
2. Materials & methods
Selection of samples for clonal sequencing analysis:
Collectively among the three trials 289 patients included in the
full data set analysis received vaniprevir-based treatment
(Hayashi et al., 2016; Kumada et al., 2016). These included 196
patients (191 gt1b, 5 gt1a) in the treatment-naïve study PN043
(Hayashi et al., 2016), 51 patients (all gt1b) in the relapse to prior
Peg-IFN treatment study PN044 (Kumada et al., 2016), and 42
patients (all gt1b) in the null-response to prior Peg-IFN treatment
study PN045 (Kumada et al., 2016). Selected samples of patients in
the vaniprevir arms from all three PhIII vaniprevir trials were
included. For each trial, baseline samples of all virologic failures
(37 gt1b, 1 gt1a) and a similar or greater number of patients from
each trial who achieved SVR24 (collectively 41, all gt1b) were
analyzed. Previous studies using direct sequencing established
that the cause for virologic failure, principally the emergence of
mutations at D168, was shared among patients from all three
trials. Therefore patient data from the three trials were pooled for
analysis at baseline for patients who achieved SVR24 versus
virologic failure to increase the size of the data set for analysis.
Samples of SVR patients were selected to include representation
of the distinct baseline polymorphisms previously detected by
direct sequencing (Hayashi et al., 2016; Kumada et al., 2016). For
sequential analysis of virologic failure patients, additional sam-
ples collected at or close to the time of failure and in the follow-up
(FU) observational period when available were selected for the
analysis. All samples were collected with written informed
consent.
To simplify discussion of the phylogenetic analysis, virologic
failure patients are referred to as non-SVR patients, and sequences
from virological failure patients as non-SVR sequences.
Analysis of Resistance Associated Mutations: Analysis focused
on variants at residues previously associatedwith treatment-failure
to the class of HCV protease inhibitors including vaniprevir (for a
review see Lontok et al., 2015), commonly referred to as Resistance
Associated Variants (RAVs). These residues include V36, Q41, F43,
T54, V55, Y56, Q80, S122, R155, A156, D168, and I/V170. All amino
acid variants at any of these residues were considered in the
analysis. The rational drug design of vaniprevir (Liverton et al.,
2008), focusing on maximizing inhibitor binding interactions
within the peptide binding pocket of the protease domain, as well
as the demonstration that natural sequence variation outside of
these deﬁned RAVs has little impact on vaniprevir potency,
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ciﬁcally linked to resistance to protease inhibitors in prior or cur-
rent clinical trials.
Clonal sequencing A total of 156 samples of RT-PCR amplicon of
HCV NS3 (800 bp or ~ 2800 bp) were retrieved from Janssen Di-
agnostics BVBA (JDx) where direct sequencing had been conducted,
and sent to WuXi AppTec for clonal isolation and sequencing. For
amplicons containing the full-length NS3 (~2800 bp), an additional
round of nested PCR was used to amplify the region encoding the
protease domain (amino acids 1e181) using two sets of primers
(Table 1). The protease PCR amplicons (~800 bp) were puriﬁed
using the QIAquick Gel Extraction kit (Qiagen, Hilden, Germany),
and ligated into pGEM®-T Easy Vector using the pGEM-T Easy
Vector System I (Promega, Madison,WI, USA). The competent E. coli
cells (Tiangen, Shanghai, China) were transformedwith the ligation
products, and the resulting transformants were plated on bacterial
agar, from which individual sequence plasmids (40 per amplicon)
were puriﬁed using standard molecular biology techniques. Iso-
lated plasmids were sequenced using the BigDye terminator v3.1
cycle sequencing kit (Applied Biosystems, Foster City, CA, USA) and
T7/SP6 primers. Capillary electrophoresis for DNA sequencing was
performed on 3130  1 Genetic Analyzer (Applied Biosystems,
Foster City, CA, USA). PCR conditions and other standard experi-
mental details are available upon request.
DNA Sequence Data Analysis: The DNA sequences of the pro-
tease domain from all cloned fragments were aligned by a program
(Sanger DNA Annotation Program 1.0, SDAP 1.0) developed at WuXi
AppTech with reference sequences of HCV gt1a (NCBI Accession
number NC_004102) and gt1b (NCBI Accession number AJ238799).
A cross-match programwas used to identify mutations in 40 clones
of each sample, and the percentage of the amino acid change of
each position in the 40 clones was also generated by this program.
To reduce inclusion of mutations generated by PCR or another
artifact of the sequencing protocol, a mutation or variant was
required to be present in at least 2 clones per sample. Hence the
detection limit is 5% (minimum 2 of 40 clones). In evaluating the
change in prevalence of a mutation between samples collected at
different time-points, a minimal change of 10% (4 clones) was set as
the threshold to be considered a change to minimize inclusion of
differences due to minor statistical ﬂuctuations.
SVR versus non-SVR Evolutionary Analyses: Samples from 39
gt1b SVR patients and 36 gt1b non-SVR patients (virologic failures)
were included in the baseline comparison to ascertain the effect of
the baseline sequence on the probability of failure. To see if non-
SVR patients shared genetics predictive of the failure state, a
phylogenetic approach was taken. Baseline sequences were aligned
using the software package MUSCLE (Edgar, 2004). Next the
alignment was used to estimate a maximum likelihood (ML) phy-
logeny in the software package PhyML (Guindon et al., 2010) under
a GTR þ G þ I model of nucleotide evolution. A cladistic method
(Maddison and Maddison, 2001; Slatkin and Maddison, 1989) was
used to investigate whether there is an evolutionary shared signal
among the non-SVR patients. The expectation is that if there is
shared genetics among the infecting non-SVR viruses, those virusesTable 1
DNA primers for nested PCR.
1st Set
1a forward primer 50-ACATCATCAACGGCYTGCCCGTCTC-30
1a reverse primer 50-TAYGCRGCCGGGACCTTRGTGCT-30
2nd set
1b forward primer 50-ACTGCGGCATGTGGGGACATC-30
1b reverse primer 50-ARGACGAGYACCTTRTACCCTTG-30would be more evolutionarily related to each other than to viruses
obtained from SVR patients. The estimated ML phylogenetic tree
was used to map the number of potential transition events using
parsimony (MacClade) (Maddison and Maddison, 2001). Specif-
ically, two-state characters were created such that sequences
derived from non-SVR and SVR patients were assigned to 1 and 2,
respectively. The number of transitions from State 1 to State 2 or the
reverse in the phylogenetic tree was then recorded. If all sequences
from non-SVR patients were monophyletic, the maximum number
of character state changes would be equal to one in one direction
and zero in the other. If, however, sequences from non-SVR patients
were more closely related than to those from SVR patients, the
number of character state changes would increase. Therefore the
most parsimonious estimate of the minimum number of viral ex-
changes between non-SVR and SVR is predicated on the basis of the
estimated maximum likelihood phylogenetic tree. To ascertain the
statistical signiﬁcance level of shared genetics, the observed num-
ber of transitions between non-SVR and SVR states within the ML
phylogeny was recorded, and this observed value then compared to
the values derived from 1000 random trees, each having identical
numbers of non-SVR and SVR sequences andwhere it is known that
the shape of the trees (ie. the SVR and non-SVR positions on the
tree) was not driven by a shared genetic signal. The p-value is the
stacked rank value where the observed transition number falls in
the distribution of the 1000 randomly generated transition
numbers.
Individual patient phylogenetic analysis: Individual patient
ML trees were estimated using the methodology described above
and the clonal sequence data generated from the speciﬁc patient's
sequentially collected samples. The ﬁve to six digit numbers asso-
ciated with each entry are individual clone numbers assigned to
track the sequencing data.
Phylogenetic Analysis of Resistance Co-variation: Samples of
36 out of 38 non-SVR patients in total among the three studies were
included in the phylogenetic analysis of sequentially collected
samples. As the majority of patients enrolled in these studies were
infected with gt1b virus, the analysis focused on gt1b sequences to
avoid possible skewing of results due to gt1a subtype differences.
Only one non-SVR patient (Patient 26, Sup. Table 1B5) was excluded
due to infectionwith gt1a virus. One other non-SVR patient (Patient
37, Sup. Table 1B16) was excluded because only baseline sequences
were available for this patient. For each patient all time points were
included in the analysis, including samples collected at multiple
times during the FU period as available.
Two deﬁned methods, both supported by established software
packages, were used for sequence analysis. The method of Gilbert
et al. (Gilbert et al., 2005). was used for the alignment based
method. This software package is implemented in the R statistical
environment and tests for co-variability of pairs of positions within
a single alignment of amino acids. The results are expressed as p-
values where the null is based on a chance alone expectation. The
software does an exhaustive search testing all possible pairs of
amino acids for correlation. The resulting p-values are then
adjusted for multiple testing. In these studies, virologic failure to
vaniprevir was attributed principally to the emergence of muta-
tions at R155 or D168 (Hayashi et al., 2016; Kumada et al., 2016). As
a consequence of this prior observation, results were constrained
only to those that included a R155 or D168 mutation.
The protease DNA sequenceswere codon aligned in the software
packageMuscle (Edgar, 2004) and then converted from codons into
amino acids to give rise to the protein alignments. The alignment-
based method only requires an amino acid alignment. The align-
ment data were fed into the Gilbert et al. (Gilbert et al., 2005)
software package using the paired sites algorithm.
The phylogenetic package HyPhy, developed by Pond et al.
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under selective forces while explicitly avoiding the confounding
effects of the alignment based methods. This method, an extension
of Felsenstein's approach (Felsenstein, 1985), redirects the focus of
comparative study from patterns in the end products of evolution
to patterns in the process of evolution itself (Poon et al., 2008). We
are looking for residues that ‘co-evolve’, such that a substitution at
one site accelerates the substitution rate at one or more other sites.
Speciﬁcally, when drug resistance arises at D168, is there a subse-
quent directional evolutionary event elsewhere within the NS3
protease domain? These jointly evolving mutations may then be
mapped to branches of the phylogenetic tree by comparing char-
acter states at each codon site both at the start and end of each
branch. If the reconstructed/observed character states are different,
then a mutation must have occurred at some point along the
branch (Tuff and Darlu, 2000). This mapping procedure does not
account for cases where more than one substitution occurs at the
same codon site in a branch, but there is a method (Dutheil et al.,
2005) that can account for these ‘multiple hits’. When the distri-
butions of mutations mapped to branches of the tree are signiﬁ-
cantly correlated between two codon sites, this outcome is
interpreted as evidence of an epistatic interaction, i.e. a synergistic
effect resulting from the speciﬁc combination of mutations. HyPhy
does exactly this in a Bayesian graphical model. Hence the results
are not rejection based but rather Bayesian. Bayesian estimation
can be interpreted as the posterior probability of the hypotheses (in
this case two sites are co-evolving) given a collection of data (in this
case codon aligned sequence data).
A maximum likelihood (ML) tree was estimated from the codon
alignment of the sequence data with the software package PhyML
(Guindon et al., 2010) with a general time-reversible nucleotide
model of evolution. The resulting ML tree and codon alignment
were brought into HyPhy to estimate epistasis across the entire
sequence alignment. The reconstruction of ancestral sequences at
each of the nodes of the tree bymaximum likelihood is increasingly
uncertain with an increase depth in the tree, i.e., further from the
observed sequences. To address this uncertainty, a non-parametric
bootstrap procedure was used to re-sample ancestral sequences
(100 replicates) from the posterior probability distributions of
character states at each internal node of the tree running the
Bayesian network analysis on each of these bootstrap replicates.
3. Results
3.1. Baseline analysis
Baseline sequences of SVR and virologic failure patients wereTable 2
Baseline RAVs.
Treatment outcome SVR Virologic failure
No. patients in analysis (gt1b) 41 38
No. patients with baseline RAVs 39 31
Reference reside RAV:# pts RAV:# pts
V36 L:1 A:1
Q41 none R:1
F43 none none
T54 S:6 S:3
V55 A:1 A:1
Y56 F:17 F:8
Q80 K:2; L:18 L:8
S122 C:1; G:6; N:2; T:1 G:8; T:4
R155 none none
A156 none none
D168 E:6; G:1; T:2; V:1 none
V170 I:27 I:17evaluated across the protease domain to compare the distribution
of baseline RAVs between the two populations (Table 2). For this
analysis a RAV is included if it met the minimal detection criteria
(two clones or minimum 5%) but does not take into account the
actual prevalence within the sample.
There were similar distributions of baseline RAVs between pa-
tients who achieved SVR and those who failed. Common baseline
RAVs included residues T54 (14.6% SVR, 7.9% non-SVR), Y56 (41.5%
SVR, 21.1% non-SVR), Q80 (48.8% SVR, 21.1% non-SVR), S122 (24.4%
SVR, 31.6% non-SVR), and V170 (65.9% SVR, 44.7% non-SVR).
However, it is noted that among the SVR patients were 9 pa-
tients with baseline RAVs at D168. This included a patient with a
D168 T/V mixture (Patient 9: 25% T, 5% V, Sup. Table 1A9), both of
which confer a large potency loss to vaniprevir (Hayashi et al.,
2016). None of the non-SVR patients had D168 RAVs detected at
baseline.
Fig. 1 shows the clustering of SVR versus non-SVR sequences at
baseline across the entire protease domain. The SVR and non-SVR
branches show a distribution similar to that from a random dis-
tribution around the phylogenetic tree. In particular the non-SVR
sequences show a clustering level of 24 (Fig. 1), in line with the
expectation of random distribution (David Nickle, unpublished
observations). The general lack of clustering of non-SVR baseline
sequences suggests that there are no obvious genetics that predict
the non-SVR state.
3.2. Resistance: longitudinal sample analysis of patients who did
not achieve SVR
Longitudinal analysis was performed on samples collected from
patients who failed vaniprevir-based regimens, with RAVs followed
among samples collected at baseline, failure, and FU. Note that the
time of failure or FU may differ among the patients.
A PN043: Treatment Naïve Patients
An evaluation of RAVs at baseline, failure, and FU for 14 patients
who failed vaniprevir-based treatment in PN043 and for which
baseline, failure, and FU data are available is presented in Table 3.
The most striking changes occurred at residue D168 (Table 3).
Although there were no patients with baseline D168 RAVs, 13 of 14
patients (92.9%) had V, H, or T RAVs at failure, all of which cause
signiﬁcant potency losses to vaniprevir (Hayashi et al., 2016), with
D168V the most common. D168 mutations were still present at FU,
but the number of patients with D168 mutations declined from
13 at failure (92.9%) to 6 (42.9%).
Patient 30 (Sup. Table 1B9) provides an interesting example of
the complex viral dynamics observed among some of these pa-
tients. Multiple viral species were present at baseline, with Y56F,
Q80L, S122T, and V170I distributed among the baseline viral species
in multiple combinations (Fig. 2a). While D168H was not detected
at baseline, it emerged speciﬁcally in the background of one of
these baseline variants, a variant encoding S122T:V170I. By FU24
D168H was barely detectable, replaced by the S122T:V170I variant
that now became the principle circulating viral species. Other
baseline variants were no longer observed in follow-up. Phyloge-
netic analysis supports the concept that the D168H variant singly
evolved among multiple viral species present at baseline (Fig. 2b).
Patient 36 (Sup. Table 1B15) had D168V virus at failure at a
prevalence of ~20% (Fig. 3). It is noted that this patient was previ-
ously reported to have failed without detectable resistant virus
based upon direct sequencing (Hayashi et al., 2016).
The prevalence of RAVs at other residues included in the analysis
differs little among the timepoints. Mutations at T54, Y56, S122,
and V170 were the most commonly observed among the patients.
Fig. 1. The maximum phylogenetic tree for baseline viral sequences obtained from SVR and non-SVR Japanese patients. Sequences were aligned, a maximum likelihood (ML)
phylogeny estimated, and a cladistic method used to investigate the likelihood of an evolutionary shared signal among non-SVR patients as described in the M &M. Green branches
represent viruses from patients who achieved SVR while red are from patients that are non-SVR. The genetic distance scale bar indicates the number of nucleotide substitutions per
site between sequences.
Table 3
Sequential analysis of resistance-associated variants among treatment naive pa-
tients who failed vaniprevir treatment in protocol PN043.
Sample time-point Baseline Failure Follow-up
No. pts in set 14
No. pts with RAVs 10 14 13
reference residue RAV:# pts RAV:# pts RAV:# pts
V36 none none A:1
Q41 none none none
F43 none none none
T54 S:1 none A:1
V55 none A:1 none
Y56 F:2 F:1 F:1
Q80 L:2 L:1 none
S122 G:3; T:2 G:2; T:3 G:2; T:2
R155 none K:1 K:1
A156 none none none
D168 none H:1: T:1; V:11 H:1; T:1; V:4
V170 I:7 I:7 I:8
Table 4
Sequential analysis of resistance-associated variants among prior treatment failures
to IFN-based treatment who failed vaniprevir treatment in Protocol PN044.
Sample time-point Baseline Failure Follow-up
No. pts in set 3
No. pts with RAVs 3 3 2
reference residue RAV:# pts RAV:# pts RAV:# pts
V36 none none none
Q41 R:1 none none
F43 none none none
T54 none none S:1
V55 none none none
Y56 none none F:1
Q80 L:1 none L:1
S122 G:1 G:1 G:1
R155 none Q:1 Q:1
A156 none none none
D168 none V:3 V:2
V170 I:1 none I:1
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Table 4 evaluates RAVs across the study for the 3 patients who
did not achieve SVR24 in PN044.
At failure all three patients had D168V. Patient 49 (Sup.
Table 1D1) was previously described by direct sequencing as being
homogenous for the D168V mutation at both the failure and FU24timepoints (Kumada et al., 2016). However, clonal sequencing
analysis demonstrated that D168V virus declined in prevalence to
69% by FU24 (Sup. Table 1D1). The rest of the virus evolved into a
complexmixture of multiple viral species, none of which encoded a
RAV which confers a signiﬁcant vaniprevir potency loss. Phyloge-
netic analysis suggests that D168V evolved singly from one of
multiple baseline sequences (Fig. 4a).
Patient 50 (Sup. Table 1D2) had two resistant viral species at
A0
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Y56F:S122T
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Fig. 2. A. Virological proﬁle of failure patient 30. The viral composition was determined through sequencing the protease domain of 40 independent clones isolated from viral RT-
PCR products generated from baseline, failure, and FU Week 24 samples. The height of the bars represents the viral titer according to the Y-axis scale. For each time-point, the total
viral composition is normalized to one, with the relative representation of each viral species shown proportionally. B. ML tree of non-SVR (virologic failure) patient 30. The ML tree
was estimated as described in M &M using clonal sequence data generated from sequentially collected samples of this patient. The tree branches are colored according to the amino
acids found at codon 168: green for D168, red for D168H. The genetic distance scale bar indicates the number of nucleotide substitutions per site between sequences.
S.W. Ludmerer et al. / Antiviral Research 130 (2016) 118e129 123failure, D168V and R155Q:D168V. Phylogenetic analysis suggests
there were at least two evolutionary events (Fig. 4b), where D168V
ﬁrst evolved from D168 virus, then R155Q:D168V virus evolved
from D168V virus. Neither species was still detected at the time of
an unscheduled visit post-FU24 (Sup. Table 1D2). Patient 51 had
D168V virus at FU20 (Sup. Table 1D3, a failure time-point is not
available for this patient). Phylogenetic analysis suggests that
D168V independently evolved at least twice in this patient (Fig. 4c)
during the course of treatment. The prevalence of the D168V virus
did not appreciably change four weeks later at FU24, the last time-
point available for this patient.
C Protocol 045 Prior Null or Partial Responders to prior Interferon-
based treatment.
Table 5 evaluates RAVs observed at baseline, time of failure, and
FU for 15 of 16 patients who failed vaniprevir-based therapy in
PN045 (patient 74, Sup. Table 1F11, who failed with D168V virus atfailure, is not included in this sub-analysis due to lack of a FU
sample).
The greatest viral dynamics were again observed at residue
D168. Although no patient displayed a baseline D168 RAV, 13 of
these 15 patients had D168 RAVs at failure (patient 64 had a D168T/
V mixture at failure, 75 % T, 25 % V, Sup. Table 1F1; patient 69 had a
D168T/Y mixture at failure, 75 % T, 25 % Y, Sup. Table 1F6). These
included D168H, T, V, or Y, all of which confer large potency losses
to vaniprevir (Hayashi et al., 2016). D168V was the most common
with 7 patients having this RAV. The D168 RAVs did not always
persist into follow-up, with only 5 patients (33.3%) still displaying
D168 RAVs by FU24 (patient 71 had a D168A/V mixture at FU24, 87
% V, 12 % A, Sup. Table 1F8). R155Q was not observed at failure, but
was also noted at low prevalence in 2 patients at FU24 (patients 65
and 77, Sup. Table 1F2 and 1F14).
RAVs at Y56, Q80, R122, and V170were common at baseline, but
there were few changes in prevalence at these residues during the
course of the study.
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Fig. 3. Virological proﬁle of failure patient 36. The viral composition was determined
through sequencing the protease domain of 40 independent clones isolated from viral
RT-PCR products generated from baseline, failure, and FU Week 24 samples. The height
of the bars represents the viral titer according to the Y-axis scale. For each time-point,
the total viral composition is normalized to one, with the relative representation of
each viral species shown proportionally.
S.W. Ludmerer et al. / Antiviral Research 130 (2016) 118e129124The prevalence of the virus attributed to failure diminished
during FU for 11 of 16 patients (68.9%). Two patients (patients 66
and 78, Sup Table 1F13 and 1F15) had neither R155 nor D168
mutant virus at any timepoint, and a virologic cause of failure has
not been established for these patients. Data is displayed for Patient
70 (Fig. 5, Sup. Table 1F7). D168V arose in the background of one of
three distinct viruses present at baseline, and diminished in prev-
alence by FU24. Earlier direct sequencing only noted D168D/V
mixtures at both Failure and FU24, and could not determine
whether resistant virus was diminishing in prevalence at the later
timepoint (Kumada et al., 2016).
Virus from 9 patients had a D168 RAV linked to 1 or more RAVs
at Y56, Q80, S122, or V170 at failure. In all cases the D168 RAV was
not present at baseline but arose in one of the baseline viral genetic
backgrounds. Patient 65 (Sup. Table 1F2) provides an informative
example of this. Although three viral species were observed at
baseline, D168T arose in the background of a minority variant
(Fig. 6a). Phylogenetic analysis suggests that D168T virus ﬁrst
evolved from baseline wild-type D168 virus, and then this single
mutant virus underwent further evolution to R155Q:D168T virus
(Fig. 6b).
D168H was detected at low prevalence (7%) at failure for patient
67 (Sup. Table 1F4). Previously this patient was reported to not have
vaniprevir RAVs at failure by direct sequencing (Kumada et al.,
2016). Only wild-type virus was detected at FU24.
3.3. Phylogenetic analysis for evidence of epistatic co-variation with
R155 or D168 mutations
This analysis sought to explore the mechanism by which resis-
tant mutations at deﬁned sites, speciﬁcally R155 and D168, had
mutations elsewhere within the protease gene that evolved in a
compensatory or epistatic fashion. To do this two methods were
implemented, neither of which found evidence for any such
compensatory mutation that reached statistical signiﬁcance. The
ﬁrst, a phylogenetic based method that is Bayesian in nature, found
no mutations that were credibly supported to co-vary with pre-
determined mutations either at R155 or D168.
The secondmethod, an alignment basedmethodwhich does not
take the evolutionary history into account and further is known to
be optimistic in the discovery of co-varying sites, found no sites
across the entire protease domain that co-vary with either R155 or
D168 after bonferroni correction for multiple testing. The smallest
p-valued observed was p ¼ 5.05; however, after accounting for
16,290 statistical tests the corrected p-value is p ¼ 0.81. Thissuggests no co-variation among sites, including no co-variation
with the predetermined R155 or D168 resistant variants.
Although neither method failed to detect co-variation with
drug-induced mutations at R155 or D168, evidence for co-variation
among other sites was observed using the Bayesian tree based
approach (Table 6). Co-variation with posterior probability
values > 0.6 was observed for residue pairs R123 with L106, G140
with L143, D79 with R123, and G137 with C16. None of these sites
have previously been linked to drug resistance (Lontok et al., 2015).
In contrast, posterior probability values for co-variation of R155 or
D168 with any other residue within the protease domain were all
less than 0.4, an extremely low value that supports the notion of
non-covariation. While the basis for co-evolution at these sites is
obscure, these events appear unrelated to the emergence of mu-
tations at R155 or D168 which resulted as a consequence of vani-
previr treatment.
4. Discussion
Resistance analysis of the vaniprevir Phase III studies was
initially conducted by direct sequencing and concluded that for
those patients who did not achieve SVR, the cause of failure was
principally due to the emergence of RAVs at R155 or D168 during
treatment (Hayashi et al., 2016; Kumada et al., 2016). Baseline RAVs
were noted at other positions including Y56, Q80, and V170, but
these RAVswere not attributed to failure for three reasons. First, the
prevalence of RAVs at these positions changed little between
baseline and failure. This contrasts to the dynamics of mutations at
R155 or D168 where typically the mutations were not present at
baseline, emerged at failure, and in the case of D168 mutations
diminished in prevalence by FU24. Second, baseline RAVs at posi-
tions other than R155 or D168 were similarly common among pa-
tients who achieved SVR and hence didn't correlate with outcome.
Finally, mutations at residues other than R155, A156, or D168 have
minimal tomodest effects on vaniprevir potency (<8.2-fold), unlike
mutations at R155 or D168 which cause potency shifts of 40-fold or
greater (Hayashi et al., 2016). We note that it has previously been
reported that baseline RAVs at residues 155 or 168 are not typically
observed among patients who are treatment-naïve to protease
inhibitors (Sarrazin, 2016).
It is commonly known that R155K mainly emerges in gt1a
virological failures because of a favorable codon shift of only one
nucleotide substitution to induce this mutation, whereas among
gt1b patients the R155K mutation is infrequently observed at fail-
ure due a requirement for a two nucleotide mutation to alter any of
the arginine codons speciﬁc to this subtype to lysine (Lontok et al.,
2015). In earlier PhII studies of vaniprevir plus Peg-IFN/R studies
conducted outside of Japan inwhich there were higher enrollments
of gt1a patients, R155K virus was in fact commonly observed at
failure among those gt1a patients who did not achieve SVR24
(Rodriguez-Torres et al., 2014). Furthermore, in the PhIII study
conducted in Japan (PN043) it was conﬁrmed that virus from the
gt1b patient who had R155K at failure (Sup. Table B5) did undergo
an uncommon two base mutation (Hayashi et al., 2016).
This work provides further evidence that baseline viral se-
quences were similar between patients who achieved or did not
achieve SVR (Tables 2 and 3). Comparable distributions of poly-
morphisms at Y56, Q80, S122, and V170 were observed between
the two populations, with only minor differences noted at other
positions associated with protease resistance. Low-level baseline
RAVs at R155 or D168 were not detected among any of the 38
virologic failures, at least to the level of sensitivity achieved in this
analysis (~5%).
It is informative to compare the viral dynamics observed in
these vaniprevir studies to that reported among similar studies of
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Fig. 4. A. ML tree of non-SVR (virologic failure) patient 49. The ML tree was estimated as described in M & M using clonal sequence data generated from sequentially collected
samples of this patient. The tree branches are colored according to the amino acids found at codon 168: green for D168, red for D168V. The genetic distance scale bar indicates the
number of nucleotide substitutions per site between sequences. B. ML tree of non-SVR (virologic failure) patient 50. The ML tree was estimated as described in M & M using clonal
sequence data generated from sequentially collected samples of this patient. The tree branches are colored according to the amino acids found at codon 168: green for D168, blue for
D168V, and red for R155Q:D168V. The genetic distance scale bar indicates the number of nucleotide substitutions per site between sequences. C. ML tree of non-SVR (virologic
failure) patient 51. The ML tree was estimated as described in M &M using clonal sequence data generated from sequentially collected samples of this patient. The tree branches are
colored according to the amino acids found at codon 168: green for D168, red for D168V. The genetic distance scale bar indicates the number of nucleotide substitutions per site
between sequences.
S.W. Ludmerer et al. / Antiviral Research 130 (2016) 118e129 125other HCV protease inhibitors administered in combination with
Peg-IFN/R studies to Japanese gt1 patients. Both simeprevir and
telaprevir are approved in Japan as components of Peg-IFN/R based
treatments, and deep sequencing data is available for some of the
patients who failed in the late stage trials of these inhibitors (Akuta
et al., 2013a, 2013b, 2014). Virologic failure to simeprevir or
telaprevir correlated with the emergence of de novo resistance
variants during treatment. Low levels of baseline resistant variants
at residues R155, A156, or D168 that were observed in some pa-
tients typically did not further emerge during treatment. Similar to
what was reported for vaniprevir (Hayashi et al., 2016), it was
concluded from these studies that baseline mutations were not
predictive of failure to telaprevir or simeprevir in Peg-IFN/R based
regimens in the Japan-based studies (Akuta et al., 2013a, 2013b,
2014).Further analysis of entire NS3 protease sequences provided no
evidence for clustering of baseline non-SVR sequences relative to
baseline SVR sequences beyond a chance probability. This suggests
the unlikelihood of a genetic signature which might identify pa-
tients likely to fail vaniprevir treatment. If there were shared ge-
netics driving the non-SVR state, then one might anticipate
clustering to be non-random such that those patients who did not
achieve SVR are more likely to share a common viral ancestor ge-
netic state distinct from those patients who achieved SVR. The
observed p-value is 0.5 (David Nickle, data not shown); thus the
null hypothesis that the two states are random with no clearly
shared genetics cannot be rejected. However, it does not necessarily
follow from a failure to reject the null distribution that the null
hypothesis is true. Rather, we draw from the lack of clustering as
demonstrated in Fig. 1 that there are no obvious viral genetics that
C0.04
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Fig. 4. (Continued).
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Table 5
Sequential analysis of resistance-associated variants among null responders to IFN-
based treatment who failed vaniprevir treatment in Protocol PN045.
Sample time-point Baseline Failure Follow-up
No. pts in set 15
No. pts with RAVs 13 14 12
reference residue RAV:# pts RAV:# pts RAV:# pts
V36 none A:1 none
Q41 none none none
F43 none none none
T54 none none none
V55 none A:1 none
Y56 F:4 F:2 F:2
Q80 L:2 H:1; L:2 L:2
S122 G:4; T:2 G:3: T:1 G:3: T:1
R155 none none Q:2
A156 none none none
D168 none H:2; T:4; V:7; Y:2 A:1; T:2; V:3
V170 I:8 I:6 A:1; I:6
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Fig. 5. Virological Proﬁle of failure patient 70. The viral composition was determined
through sequencing the protease domain of 40 independent clones isolated from viral
RT-PCR products generated from baseline, failure, and FU Week 24 samples. The height
of the bars represents the viral titer according to the Y-axis scale. For each time-point,
the total viral composition is normalized to one, with the relative representation of
each viral species shown proportionally.
S.W. Ludmerer et al. / Antiviral Research 130 (2016) 118e129 127predict the non-SVR state, at least among the Japanese gt1b pa-
tients enrolled in these trials.
Baseline D168 RAVs were noted among 9 patients who achieved
SVR on this regimen. Six of these patients had D168E (Sup. Table.
A3, A5, A11, A12, A18, and C1), a somewhat common variant
which confers only a modest potency loss to vaniprevir (~40-fold in
the gt1b background (Hayashi et al., 2016)), and for which a result
of SVR is not entirely unexpected. However, there also was one
patient with baseline D168T (Sup. Table. E5), one patient with
baseline D168G (Sup. Table. E4), and one patient with both D168T
and D168V (Sup. Table. A9), all of which confer signiﬁcant potency
vaniprevir potency losses of >400 fold (Hayashi et al., 2016), and
have previously been associated with failure to vaniprevir by direct
sequencing (Hayashi et al., 2016; Kumada et al., 2016; Rodriguez-
Torres et al., 2014). Thus the data suggest that detection of a low
level of D168 resistant virus at baseline does not by itself predict
failure to a vaniprevir-based regimen.
In the majority of cases the prevalence of resistant virus
attributed to vaniprevir failure diminished during the FU period.
Establishing a 10% decrease in viral prevalence as the threshold to
consider a variant receding, then 24 of 32 non-SVR patients with
full study sample sets available showed reduced prevalence of
resistant virus during the protocol deﬁned FU period, accompanied
with a return of wild-type virus.
The D168V mutation confers among the highest in vitro potency
loss to vaniprevir (>590-fold relative to wild-type) of any protease
mutation (Hayashi et al., 2016). Furthermore, D168V virus was the
most frequently observed virus to emerge during treatment, and
was detected at failure in 21 of 38 virologic failures (Sup. Tab. B, D,&
F). However, it also rapidly disappeared, and by FU24 was no longer
detectable by clonal sequencing in 12 of these 21 virologic failures.
Previously the D168V mutation was shown to reduce replication
ﬁtness to 43% relative to wild-type in the in vitro gt1b replicon
system (He et al., 2008). In this same work, the investigators dis-
cussed the concept of ‘selective advantage curve’, whereby the
relative prevalence of a viral variant was amulti-factorial balance of
drug concentration, mutant drug susceptibility, and mutant repli-
cation capacity, collectively determining the replication level of a
speciﬁc viral variant at a given drug concentration. The selective
advantage of D168V virus at high drug concentrations coupled with
its replication impairment may account for the high prevalence of
D168V virus at failure followed by its rapid disappearance off-drug
as observed in these studies.
Analysis of sequences obtained from sequentially collected
samples of 36 failure patients, all gt1b, provided no evidence forsecond site co-evolution with either R155 or D168. Pairwise anal-
ysis using either the alignment or phylogenetic based methods
gave non-signiﬁcant probabilities that an evolutionary event at
residue 155 or 168 was linked to a similar event elsewhere within
protease. This is not to say that co-evolutionary pressure was ab-
sent. The same phylogenetic analysis showed evidence for co-
variation of residues G137 with C16, D79 with R123, R123 with
L106, and G140 with L143, although none of these pair-wise vari-
ations were predicted by the alignment based method. Hence
phylogenetic analysis supports the earlier conclusions derived from
direct-sequencing of the same sample set that virologic failure to
vaniprevir was due solely to the presence or emergence of muta-
tions at residue 155 or 168, and cannot be anticipated by the
presence of speciﬁc substitutions or polymorphisms elsewhere
within the protease domain.
The ﬁndings of this work are based on data generated from
patients treatment-naïve to protease inhibitors or other direct-
acting antiviral agents. Subsequent to this work, a variety of regi-
mens comprised exclusively of direct-acting antiviral agents have
become available. The effect if any of prior treatment with a pro-
tease inhibitor or other direct-acting antiviral agents on the pa-
rameters discussed in this work requires a separate evaluation.
In summary, the results of this data generated from clonal
sequencing are consistent with the earlier interpretation guided by
direct sequencing, and support the following additional conclu-
sions. Baseline polymorphisms were similarly common among
both SVR and non-SVR patients and did not appear to inﬂuence
outcome to vaniprevir-based treatment. In addition, there is no
evidence for a baseline signature sequence among non-SVR pa-
tients which distinguishes them from SVR patients, and which may
be predictive of a pre-disposition to failure to a vaniprevir based
regimen. Low prevalence of a D168 RAV at baseline is not neces-
sarily predictive of treatment failure to vaniprevir. Among the
majority of patients who failed the regimen, the prevalence of the
resistant variant diminished during the protocol deﬁned FU period.
Finally, there is no evidence for co-evolution of second-site muta-
tions with emerging R155 or D168 mutations among patients who
failed vaniprevir-based treatment.
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Fig. 6. A. Virological Proﬁle of failure patient 65. The viral composition was determined through sequencing the protease domain of 40 independent clones isolated from viral RT-
PCR products generated from baseline, failure, and FU Week 24 samples. The height of the bars represents the viral titer according to the Y-axis scale. For each time-point, the total
viral composition is normalized to one, with the relative representation of each viral species shown proportionally. B. ML tree of non-SVR (virologic failure) patient 65. The ML tree
was estimated as described in M &M using clonal sequence data generated from sequentially collected samples of this patient. The tree branches are colored according to the amino
acids found at codon 168: green for D168, red for virus species D168T or R155Q:D168T. The genetic distance scale bar indicates the number of nucleotide substitutions per site
between sequences.
Table 6
Bayesian posterior probability of site 1 evolving with site 2.
Site 1 Site 2 P value: Site1 to Site 2
R123 L106 0.82
G140 L143 0.79
D79 R123 0.71
G137 C16 0.63
R155 Any other residue within 1e180 <0.04
D168 Any other residue within 1e180 <0.04
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